Leaderboard

En | De
No articles selected!     View Cart  
You are here: Urology-Nephrology » Neoplasia/BPH 09. October 2026
Search
medline.ch
Neoplasia/BPH
Advanced search
Dermatology
Endocrinology
Nutrition
Gastroenterology
Gynecology
Haematology
Infectious diseases
Cardiovascular Diseases
Musculoskeletal Diseases
Neurology
Oncology
ORL
Pediatrics
Psychiatry
Respiratory Tract
Sports
Urology-Nephrology
Inflammation-Infection
Nephrolithiasis
Renal Failure
Sexuality
Neoplasia/BPH
Others
Rect Top
Zoom: Zoom In Zoom Out

   Page 1 of 9596  Previews Next
   
   Articles 1 - 20 / 191903  
   
Preclinical Evaluation on the Radiohybrid Tandem [(18)F]La- and [(225)Ac]Ac-rhPSMA-10.1 for Targeted α-Therapy of Prostate Cancer.
J Nucl Med
Sun B, Werner D, Ni J, Weidle S, Steiger K, Seyfi S, Kossatz S, Eiber M, Morgenstern A, Bruchertseifer F, Chilug EL, Weber WA, D'Alessandria C, Wurzer A.
PMID: 42850042 [PubMed - as supplied by publisher]


A randomised, open-label, phase II study of tobemstomig combinations in patients with previously untreated advanced clear-cell renal cell carcinoma.
ESMO Open
Rini BI, Powles T, Tomczak P, Shin SJ, Guo J, Molina-Cerrillo J, Ren X, Lee JL, Wysocki PJ, Puente J, Basu A, Mar N, Bernhard S, Khan O, Ha J, Colley L, Prizant H, Albiges L.
PMID: 42849355 [PubMed - as supplied by publisher]


From validation trials to clinical reality: implementing AI-supported prostate MRI pathways in the NHS.
Br J Nurs
Adesuyi A, Singh S, Ankur M.
PMID: 42848705 [PubMed - indexed for MEDLINE]


Implementation and evaluation of a nurse-led clinic for men referred with suspected prostate cancer.
Br J Nurs
Teodorowski P, Thomson J, McInnes M, Hibberd C, McFarland A, Gadsby E.
PMID: 42848699 [PubMed - indexed for MEDLINE]


Development and Validation of a Tool to Measure Documented Health Care Encounter Time.
JAMA Netw Open
Chow R, Bayrakdarian S, Gojsevic O, MacMillan E, Balboni T, Bowen J, Bruera E, Chan RJ, Gupta A, Hart NH, Hoskin P, Hui D, Iihara H, Jefford M, Lee SF, Riechelmann R, Rugo HS, Ruhlmann CH, Simone CB 2nd, Wong HCY, Zimmermann C, Chung H, Richards GC, Heneghan C, Leigh J, MASCC Emerging Toxicities Study Group.
PMID: 42848401 [PubMed - indexed for MEDLINE]


Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: A Nonrandomized Clinical Trial.
JAMA Oncol
Qie Y, Jia K, Huang S, Zhao J, Xue Z, Guo S, Zhang T, Wu Z, Shen C, Hu H.
PMID: 42848391 [PubMed - as supplied by publisher]


Clinical efficacy and safety of second-line cabozantinib after first-line immune checkpoint inhibitor-based combinations in metastatic renal cell carcinoma: a multicenter retrospective study.
Int J Clin Oncol
Matsukawa A, Kato T, Oki M, Takao T, Inoki L, Sato M, Okada K, Maekawa T, Imanaka T, Nakayama J, Tomiyama E, Nagahara A, Ishizuya Y, Hayashi T, Yamamoto Y, Hatano K, Kawashima A, Nakayama M, Takayama H, Ono Y, Takada S, Nishimura K, Fujita K, Imamura R, Nonomura N.
PMID: 42848309 [PubMed - as supplied by publisher]


Summary of Research: Health-Related Quality-of-Life Profile and Clinical Outcomes in First-Line Advanced Renal Cell Carcinoma: A Modeling Analysis Based on the CheckMate 9ER Study.
Adv Ther
Cella D, Derosa M, Floden L, Giles RH, Lothgren M, Ogareva A, Powles T, Purnajo I, Choueiri TK, Bergerot C, Motzer RJ, Bedke J.
PMID: 42848188 [PubMed - as supplied by publisher]


Retroperitoneal lymph node dissection for isolated node recurrence of renal cell carcinoma after nephrectomy: a systematic review.
World J Urol
Costa Silva A, Clarke N, Gulamhusein A.
PMID: 42848085 [PubMed - indexed for MEDLINE]


Exploratory Analysis of Peri-Prostatic Adipose Tissue Radiomics Features and Their Potential to Predict Prostate Cancer Diagnosis: Results From a UK Biobank Study.
Prostate
O'Neill A, O'Keeffe R, Winter S, Dorrian J, Gaunt TR, Guönason V, Travis RC, Martin RM, Allott EH, Leech M.
PMID: 42847696 [PubMed - as supplied by publisher]


Characteristics and Treatment Patterns of Patients with Muscle-Invasive Bladder Cancer in the United States: A Real-World Cohort Study.
Pragmat Obs Res
Gore JL, Thompson A, Kelkar SS, Chirikov V, Kamat S, Quan W, Donnowitz K, Young C, Nimke D, Quicquaro CM, Willmon CL, Pednekar P.
PMID: 42846494 [PubMed]


Immunosuppressive cell populations as potential drivers of extrinsic immune checkpoint inhibition resistance in clear cell renal cell carcinoma.
Oncol Rev
Temuri UH.
PMID: 42846110 [PubMed]


Identifying a critical skeletal muscle threshold and systemic predictors for acute urinary retention in benign prostatic hyperplasia with sarcopenia: an internally validated model.
Front Endocrinol (Lausanne)
Yang Q, Xu Y, Hou S, Yang B, Huang L.
PMID: 42845696 [PubMed - indexed for MEDLINE]


Improved survival in newly diagnosed metastatic prostate cancer: a National Prostate Cancer Audit study.
BJU Int
Nathan A, Parry MG, Mayne E, Cook A, Liu J, Varma R, Cuningham W, Dodkins J, Parry M, Nossiter J, Aggarwal A, van der Meulen J, Tree A, Clarke N.
PMID: 42845147 [PubMed - as supplied by publisher]


MITF-Overexpressing Perivascular Epithelioid Cell Tumor of the Urinary Bladder Lacking TSC1/TSC2 Alterations and TFE3 Rearrangement: A Case Report and Review of the Literature.
Pathol Int
Jeong JI, Lee J, Oh MH, Cho HD, Lee JH, Jeon YS, Jang SH.
PMID: 42844916 [PubMed - indexed for MEDLINE]


Longitudinally Monitoring Prostate Cancer Bone Metastasis and Treatment Response via Circulating Extracellular Vesicles.
J Extracell Vesicles
Gentile E, Corn PG, Zavridou M, Long JP, Song JH, Hoang A, Hahn AW, Dondossola E, Norton W, Lin SH, Logothetis CJ, Panaretakis T.
PMID: 42844644 [PubMed - indexed for MEDLINE]


A novel "early warning" system for biochemical recurrence in prostate cancer: development and validation of the SII-HALP combined score.
BMC Cancer
Wang Y, Fu G, Han D, Ye D.
PMID: 42844604 [PubMed - indexed for MEDLINE]


Critical appraisal of artificial intelligence studies for prostate cancer detection on MRI.
Eur Radiol
Pooch E, Agrotis G, Schoots IG, Emberton M, Kasivisvanathan V, Hu Y.
PMID: 42844397 [PubMed - as supplied by publisher]


Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis.
Nat Commun
Kong W, Xu Y, Liu G, Lv W, Wang Z, Cao D, Jiao F, Hu J, Wu X, Huang J, Chen Y, Zhai W, Wu X, Pan J, Huang Y, Wu G, Zheng L, Xue W, Zhang J.
PMID: 42844281 [PubMed - indexed for MEDLINE]


Younger Age Is Associated With Slower PSA Decline After Low-Dose-Rate Brachytherapy for Localized Prostate Cancer.
Int J Urol
Nakai Y, Onishi K, Miyake M, Yamaki K, Isohashi F, Asakawa I, Tanaka N.
PMID: 42844157 [PubMed - indexed for MEDLINE]


   
   Articles 1 - 20 / 191903    Page 1 of 9596  Previews Next

 
Rect Bottom
Adserver Footer
 

  Time frame  
   

Sky right 1